Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple system atrophy.

E Siemers1

  • 1Department of Neurology, Indiana University School of Medicine, Indianapolis, USA.

The Medical Clinics of North America
|March 27, 1999
PubMed
Summary

Multiple System Atrophy (MSA) is a complex neurological disorder. Identifying glial inclusion bodies helps classify MSA subtypes, paving the way for understanding its pathology and developing effective treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aß Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan.

The journal of prevention of Alzheimer's disease·2023
Same author

The Ups and Downs of Amyloid in Alzheimer's.

The journal of prevention of Alzheimer's disease·2022
Same author

Commentary: Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.

The journal of prevention of Alzheimer's disease·2019
Same author

What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force.

The journal of prevention of Alzheimer's disease·2018
Same author

Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer's Disease in EXPEDITION 3.

The journal of prevention of Alzheimer's disease·2018
Same author

Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2018

Area of Science:

  • Neurology
  • Pathology
  • Neurodegenerative Diseases

Background:

  • Multiple System Atrophy (MSA) presents complex challenges in pathology, etiology, diagnosis, and treatment.
  • Current symptomatic treatments, like neurotransmitter replacement, offer limited efficacy due to widespread pathology.
  • Effective treatments for MSA require understanding and halting disease progression.

Purpose of the Study:

  • To establish a clear nosologic classification for MSA subtypes.
  • To investigate the diagnostic significance of intracytoplasmic glial inclusion bodies.
  • To differentiate MSA from other neurodegenerative diseases.

Main Methods:

  • Histopathological examination for intracytoplasmic glial inclusion bodies.
  • Comparative analysis of inclusion bodies across MSA subtypes (SND, OPCA, SDS) and familial OPCA.
  • Review of current diagnostic and treatment strategies for MSA.

Main Results:

  • Intracytoplasmic glial inclusion bodies provide evidence for classifying SND, OPCA, and SDS as a single nosologic entity (MSA).
  • The absence of these inclusions in familial OPCA suggests potential for improved diagnostic specificity and sensitivity.
  • Clear definition of MSA facilitates deeper understanding of its pathophysiology.

Conclusions:

  • Glial inclusion bodies are key diagnostic markers for Multiple System Atrophy.
  • Accurate classification of MSA is crucial for advancing research into its pathogenesis.
  • Understanding MSA pathophysiology is essential for developing targeted therapies and improving patient outcomes.

Related Experiment Videos